Netherlands· NL-319f5cec4172
Nucala 100 mg oplossing voor injectie in voorgevulde spuit
A mepolizumab product containing mepolizumab, registered in Netherlands by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Mepolizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC R03DX09 (mepolizumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Mepolizumab · ATC R03DX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MEPOLIZUMAB
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Netherlands (NL)
- ATC code
- R03DX09
- ATC class
- Mepolizumab
- Defined daily dose
- 3.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/15/1043
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mepolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceNUCALA 100 mg, solution injectable en seringue préremplieGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- IrelandNucala 100 mg solution for injection in pre-filled penGlaxoSmithKline Trading Services Limited
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaGlaxoSmithKline Trading Services Limited
- BelgiumNucala 100 mgGlaxoSmithKline Trading Services
- SpainNUCALA 100 MG POLVO PARA SOLUCION INYECTABLEGlaxosmithkline Trading Services Limited
- United KingdomNucala 100mg powder for solution for injection vialsGlaxoSmithKline UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d5941834-7b90-455b-ae50-7b1b13cbdd96 GET /v1/drugs/d5941834-7b90-455b-ae50-7b1b13cbdd96?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Mepolizumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp123821",
"excipients": [
"CITROENZUUR 1-WATER (E 330)",
"DINATRIUMEDETAAT 2-WATER",
"DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
"POLYSORBAAT 80 (E 433)",
"SACCHAROSE",
"WATER VOOR INJECTIE"
],
"substances": [
"MEPOLIZUMAB"
],
"leaflet_url": null,
"authorised_at": "2015/12/02",
"procedure_number": "EMEA/H/C/003860",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/15/1043",
"additional_monitoring": "N"
}See everything about mepolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.